{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T19:15:16Z","timestamp":1788117316091,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,30]]},"DOI":"10.7759\/cureus.115455","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T18:46:41Z","timestamp":1788115601000},"source":"Crossref","is-referenced-by-count":0,"title":["Checkpoint Inhibitor-Treated Merkel Cell Carcinoma With Cytokeratin 20 (CK20)-Negative Metastatic Immunophenotypic Divergence: Diagnostic and Therapeutic Implications"],"prefix":"10.7759","author":[{"given":"Diego","family":"Berlingeri Collazo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lester","family":"Cintron Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Torres Troche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.77","article-title":"Merkel cell carcinoma","volume":"3","author":"Becker JC","year":"2017","unstructured":"Becker JC, Stang A, DeCaprio JA, Cerroni L, Lebb\u00e9 C, Veness M, Nghiem P. Merkel cell carcinoma. Nat Rev Dis Primers. 2017, 3:17077. 10.1038\/nrdp.2017.77","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.10.022","article-title":"Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs","volume":"71","author":"Schadendorf D","year":"2017","unstructured":"Schadendorf D, Lebb\u00e9 C, Zur Hausen A, Avril MF, Hariharan S, Bharmal M, Becker JC. Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer. 2017, 71:53-69. 10.1016\/j.ejca.2016.10.022","journal-title":"Eur J Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2014.148","article-title":"Cytokeratin 20-negative Merkel cell carcinoma is infrequently associated with the Merkel cell polyomavirus","volume":"28","author":"Miner AG","year":"2015","unstructured":"Miner AG, Patel RM, Wilson DA, et al.. Cytokeratin 20-negative Merkel cell carcinoma is infrequently associated with the Merkel cell polyomavirus. Mod Pathol. 2015, 28:498-504. 10.1038\/modpathol.2014.148","journal-title":"Mod Pathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001136","article-title":"INSM1 is more sensitive and interpretable than conventional immunohistochemical stains used to diagnose Merkel cell carcinoma","volume":"42","author":"Lilo MT","year":"2018","unstructured":"Lilo MT, Chen Y, LeBlanc RE. INSM1 is more sensitive and interpretable than conventional immunohistochemical stains used to diagnose Merkel cell carcinoma. Am J Surg Pathol. 2018, 42:1541-8. 10.1097\/PAS.0000000000001136","journal-title":"Am J Surg Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2007.00759.x","article-title":"A case series and immunophenotypic analysis of CK20-\/CK7+ primary neuroendocrine carcinoma of the skin","volume":"34","author":"Calder KB","year":"2007","unstructured":"Calder KB, Coplowitz S, Schlauder S, Morgan MB. A case series and immunophenotypic analysis of CK20-\/CK7+ primary neuroendocrine carcinoma of the skin. J Cutan Pathol. 2007, 34:918-23. 10.1111\/j.1600-0560.2007.00759.x","journal-title":"J Cutan Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma","volume":"374","author":"Nghiem PT","year":"2016","unstructured":"Nghiem PT, Bhatia S, Lipson EJ, et al.. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016, 374:2542-52. 10.1056\/NEJMoa1603702","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0077","article-title":"Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial","volume":"4","author":"D'Angelo SP","year":"2018","unstructured":"D'Angelo SP, Russell J, Lebb\u00e9 C, et al.. Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial. JAMA Oncol. 2018, 4:e180077. 10.1001\/jamaoncol.2018.0077","journal-title":"JAMA Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01896","article-title":"Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy","volume":"37","author":"Nghiem P","year":"2019","unstructured":"Nghiem P, Bhatia S, Lipson EJ, et al.. Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy. J Clin Oncol. 2019, 37:693-702. 10.1200\/JCO.18.01896","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00885-w","article-title":"Pembrolizumab for the first-line treatment of recurrent locally advanced or metastatic Merkel cell carcinoma: results from the single-arm, open-label, phase III KEYNOTE-913 study","volume":"25","author":"Mortier L","year":"2024","unstructured":"Mortier L, Villabona L, Lawrence B, et al.. Pembrolizumab for the first-line treatment of recurrent locally advanced or metastatic Merkel cell carcinoma: results from the single-arm, open-label, phase III KEYNOTE-913 study. Am J Clin Dermatol. 2024, 25:987-96. 10.1007\/s40257-024-00885-w","journal-title":"Am J Clin Dermatol"},{"key":"ref10","unstructured":"National Comprehensive Cancer Network. Merkel cell carcinoma (version 2.2025). (2025). Accessed. March 8, 2026: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1444."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06300-3","article-title":"Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA","volume":"9","author":"Paulson KG","year":"2018","unstructured":"Paulson KG, Voillet V, McAfee MS, et al.. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun. 2018, 9:3868. 10.1038\/s41467-018-06300-3","journal-title":"Nat Commun"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0005","article-title":"Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma","volume":"2","author":"Paulson KG","year":"2014","unstructured":"Paulson KG, Tegeder A, Willmes C, et al.. Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma. Cancer Immunol Res. 2014, 2:1071-9. 10.1158\/2326-6066.CIR-14-0005","journal-title":"Cancer Immunol Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000000124","article-title":"Loss of cytokeratin 20 and acquisition of thyroid transcription factor-1 expression in a Merkel cell carcinoma metastasis to the brain","volume":"36","author":"Shalin SC","year":"2014","unstructured":"Shalin SC, Cifarelli CP, Suen JY, Gao L. Loss of cytokeratin 20 and acquisition of thyroid transcription factor-1 expression in a Merkel cell carcinoma metastasis to the brain. Am J Dermatopathol. 2014, 36:904-6. 10.1097\/DAD.0000000000000124","journal-title":"Am J Dermatopathol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02054","article-title":"Circulating tumor DNA assay detects Merkel cell carcinoma recurrence, disease progression, and minimal residual disease: surveillance and prognostic implications","volume":"42","author":"Akaike T","year":"2024","unstructured":"Akaike T, Thakuria M, Silk AW, et al.. Circulating tumor DNA assay detects Merkel cell carcinoma recurrence, disease progression, and minimal residual disease: surveillance and prognostic implications. J Clin Oncol. 2024, 42:3151-61. 10.1200\/JCO.23.02054","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.10.032","article-title":"Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: implications for patient management","volume":"94","author":"Akaike T","year":"2026","unstructured":"Akaike T, Thakuria M, Silk AW, et al.. Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: implications for patient management. J Am Acad Dermatol. 2026, 94:548-56. 10.1016\/j.jaad.2025.10.032","journal-title":"J Am Acad Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.815","article-title":"Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma","volume":"5","author":"Iyer JG","year":"2016","unstructured":"Iyer JG, Blom A, Doumani R, et al.. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016, 5:2294-301. 10.1002\/cam4.815","journal-title":"Cancer Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/490706-checkpoint-inhibitor-treated-merkel-cell-carcinoma-with-cytokeratin-20-ck20-negative-metastatic-immunophenotypic-divergence-diagnostic-and-therapeutic-implications","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T18:46:42Z","timestamp":1788115602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/490706-checkpoint-inhibitor-treated-merkel-cell-carcinoma-with-cytokeratin-20-ck20-negative-metastatic-immunophenotypic-divergence-diagnostic-and-therapeutic-implications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.115455","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,30]]}}}